| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |